Department of Cardiac Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Cell Transplant. 2022 Jan-Dec;31:9636897221122999. doi: 10.1177/09636897221122999.
Coronary artery bypass grafting remains the gold standard in the therapy of advanced-stage patients. But the vein grafts are prone to restenosis or failure. Pentoxifylline (PTX) is a methylxanthine derivative with a function of inhibiting cell proliferation. We thus applied PTX locally to the vein grafts to study its effect on the inhibition of graft restenosis using a rat vein graft model. Morphometric results showed a significant decrease in the thickness of vein grafts intimal and medial at day 28 after the bypass operation. Results from Western blot and immunohistochemistry showed that PTX also significantly reduced the proliferating cell nuclear antigen (PCNA), alpha-smooth muscle actin (α-SMA) expression, and phosphorylation of p38 in vein grafts. These results firstly discovered the positive role of PTX in preventing the vein grafts restenosis and the mechanism may be inhibition of vascular smooth muscle cells (VSMCs) proliferation via the p38MAPK pathway.
冠状动脉旁路移植术仍然是晚期患者治疗的金标准。但静脉移植物容易发生再狭窄或失效。己酮可可碱（PTX）是一种甲基黄嘌呤衍生物，具有抑制细胞增殖的功能。因此，我们将 PTX 局部应用于静脉移植物，通过大鼠静脉移植物模型研究其对抑制移植物再狭窄的作用。形态计量学结果显示，旁路手术后 28 天，静脉移植物内膜和中膜的厚度明显减少。Western blot 和免疫组织化学结果表明，PTX 还显著降低了静脉移植物中增殖细胞核抗原（PCNA）、α-平滑肌肌动蛋白（α-SMA）的表达和 p38 的磷酸化。这些结果首次发现了 PTX 在预防静脉移植物再狭窄中的积极作用，其机制可能是通过 p38MAPK 通路抑制血管平滑肌细胞（VSMCs）增殖。
